Scilex Holding Company Sets Launch Price Of $595 Per 150ml Bottle Of Gloperba, Its Liquid Oral Version Of The Anti-Gout Medicine Colchicine Indicated For The Prophylaxis Of Painful Gout Flares In Adults; Expected Plans To Launch In The First Half Of 2024
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company announced the launch of Gloperba, the first FDA-approved liquid oral colchicine for gout prophylaxis, priced at $595 per 150ml. Set to launch in the first half of 2024, Gloperba targets over 70% of gout patients with comorbid conditions requiring dose adjustments. The U.S. gout treatment market is expected to reach $2.0 billion by 2028. Scilex's direct distribution network and experienced commercial team, which successfully launched ZTlido and Elyxyb, positions it well for Gloperba's distribution.
March 05, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding Company is launching Gloperba, a novel liquid colchicine for gout, in 2024. With a strong distribution network and a successful commercial team, Scilex aims to capture a significant share of the growing gout treatment market.
The launch of Gloperba represents a significant milestone for Scilex, being the first liquid colchicine for gout prophylaxis. Given the size of the target market and Scilex's proven track record with ZTlido and Elyxyb, the introduction of Gloperba is likely to have a positive short-term impact on SCLX's stock price. The company's direct distribution network and experienced commercial team further support the potential for successful market penetration and revenue growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100